Current Challenges in Hemostasis and Advances in Particle‐Assisted Styptic Devices

TL;DR

This paper discusses challenges in stopping bleeding and highlights new technologies like microparticle-assisted dressings to improve hemostasis.

Contribution

The paper presents recent innovations in biomimetic and nanoengineered hemostatic systems with integrated drug delivery.

Findings

Current hemostatic dressings face issues like delayed activation and poor performance in severe conditions.

Microparticle-integrated and nanoengineered systems show promise in overcoming these limitations.

Biomimetic approaches and drug delivery integration are key to next-generation hemostatic devices.

Abstract

Rapid and effective hemorrhage control is critical in trauma and surgical interventions, where uncontrolled bleeding remains a leading cause of preventable death. In response to this urgent clinical demand, the development of novel hemostatic materials is the focus of increasing research interest, in both academia and industry. Styptic dressings are gradually evolving to address this need. However, significant challenges, such as delayed activation, suboptimal performance in severe conditions, and biocompatibility issues, persist. Here current limitations in hemostatic dressing technologies are explored, and recent innovations including biomimetic approaches in this field are highlighted. Special emphasis is placed on microparticle‐integrated and nanoengineered systems integrated with drug delivery technologies. By addressing these challenges, it is aimed to inspire new pathways for the development of next‐generation multifunctional dressings with enhanced efficacy and accessibility.

Here persistent limitations in hemostatic technologies are highlighted and cutting‐edge biomimetic, microparticle‐assisted, and nanoengineered systems with integrated drug delivery are showcased. Moreover, the article identifies fresh directions toward the next‐generation of multifunctional hemostatic devices with superior efficacy and accessibility, critically assessing novel strategies to overcome activation delays, performance gaps, and biocompatibility issues.

Figures